These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 8709107

  • 1. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T.
    J Med Chem; 1996 Jul 05; 39(14):2764-72. PubMed ID: 8709107
    [Abstract] [Full Text] [Related]

  • 2. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
    Unangst PC, Capiris T, Connor DT, Doubleday R, Heffner TG, MacKenzie RG, Miller SR, Pugsley TA, Wise LD.
    J Med Chem; 1997 Dec 05; 40(25):4026-9. PubMed ID: 9406594
    [Abstract] [Full Text] [Related]

  • 3. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.
    J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.
    Kesten SR, Heffner TG, Johnson SJ, Pugsley TA, Wright JL, Wise LD.
    J Med Chem; 1999 Sep 09; 42(18):3718-25. PubMed ID: 10479303
    [Abstract] [Full Text] [Related]

  • 5. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K, Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T, Usuda S, Yamaguchi T.
    Br J Pharmacol; 1996 Apr 09; 117(8):1625-32. PubMed ID: 8732269
    [Abstract] [Full Text] [Related]

  • 6. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A.
    J Pharmacol Exp Ther; 1995 Dec 09; 275(3):1239-46. PubMed ID: 8531087
    [Abstract] [Full Text] [Related]

  • 7. YM-50001: a novel, potent and selective dopamine D4 receptor antagonist.
    Hidaka K, Tada S, Matsumoto M, Ohmori J, Maeno K, Yamaguchi T.
    Neuroreport; 1996 Nov 04; 7(15-17):2543-6. PubMed ID: 8981420
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S, Chaki S, Yoshikawa R, Suzuki Y, Ogawa S, Imagawa Y, Kawashima N, Ikeda Y, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.
    J Pharmacol Exp Ther; 1997 Jul 04; 282(1):56-63. PubMed ID: 9223539
    [Abstract] [Full Text] [Related]

  • 9. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.
    J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828
    [Abstract] [Full Text] [Related]

  • 10. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 11. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL.
    J Pharmacol Exp Ther; 1998 Oct 01; 287(1):167-86. PubMed ID: 9765336
    [Abstract] [Full Text] [Related]

  • 12. Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
    Unangst PC, Capiris T, Connor DT, Heffner TG, MacKenzie RG, Miller SR, Pugsley TA, Wise LD.
    J Med Chem; 1997 Aug 15; 40(17):2688-93. PubMed ID: 9276014
    [Abstract] [Full Text] [Related]

  • 13. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
    Perrone R, Berardi F, Colabufo NA, Leopoldo M, Tortorella V.
    J Med Chem; 1998 Nov 19; 41(24):4903-9. PubMed ID: 9822559
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, Lutzke BS, Mccall RB, Piercey MF, Schreur PJ, Sethy VH, Smith MW, Svensson KA, Tang AH, Vonvoigtlander PF, Tenbrink RE.
    J Pharmacol Exp Ther; 1996 Dec 19; 279(3):1392-403. PubMed ID: 8968364
    [Abstract] [Full Text] [Related]

  • 15. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S.
    J Pharmacol Exp Ther; 1995 Nov 19; 275(2):885-98. PubMed ID: 7473180
    [Abstract] [Full Text] [Related]

  • 16. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul 19; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 17. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A.
    Behav Pharmacol; 2009 Jul 19; 20(4):303-11. PubMed ID: 19584712
    [Abstract] [Full Text] [Related]

  • 18. N-(1-Benzylpyrrolidin-3-yl)arylbenzamides as potent and selective human dopamine D4 antagonists.
    Egle I, Barriault N, Bordeleau M, Drage J, Dube L, Peragine J, Mazzocco L, Arora J, Jarvie K, Tehim A.
    Bioorg Med Chem Lett; 2004 Oct 04; 14(19):4847-50. PubMed ID: 15341937
    [Abstract] [Full Text] [Related]

  • 19. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
    Tallman JF, Primus RJ, Brodbeck R, Cornfield L, Meade R, Woodruff K, Ross P, Thurkauf A, Gallager DW.
    J Pharmacol Exp Ther; 1997 Aug 04; 282(2):1011-9. PubMed ID: 9262370
    [Abstract] [Full Text] [Related]

  • 20. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ.
    J Pharmacol Exp Ther; 1998 Oct 04; 287(1):187-97. PubMed ID: 9765337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.